Intelligence Feed event · Equity · 2026-09-20

    Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact

    Question

    Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact

    Direct answer

    Shares of Twist Bioscience increased by 31% over the weekly session following the formalization of an AI drug discovery agreement with Eli Lilly. Under the structure, Twist supplies proprietary AbLab characterization workflows into Lilly TuneLab, generating direct data services revenue while enhancing synthetic biology integration in biopharma pipelines.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-20
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact”, revision 1, evidence through 2026-09-20. https://marketontology.com/market-events/2026-09-20/twist-bioscience-shares-gain-31-on-eli-lilly-ai-drug-discovery-pact-c06ca2

    EQUITY
    Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact
    Shares of Twist Bioscience increased by 31% over the weekly session following the formalization of an AI drug discovery agreement with Eli Lilly. Under the structure, Twist supplies proprietary AbLab characterization workflows into Lilly TuneLab, generating direct data services revenue while enhancing synthetic biology integration in biopharma pipelines.
    TWSTLLY
    Impact
    71
    SEP 20
    SIG
    85%
    TWSTLLY
    Twist Bioscience shares gain 31% on Eli Lilly AI drug discovery pact
    Shares of Twist Bioscience increased by 31% over the weekly session following the formalization of an AI drug discovery agreement with Eli Lilly. Under the structure, Twist supplies proprietary AbLab characterization workflows into Lilly TuneLab, generating direct data services revenue while enhancing synthetic biology integration in biopharma pipelines.
    → Direct commercial partnership with a major pharmaceutical customer provides fee-based revenue and validates proprietary antibody discovery software models.
    Impact
    Shares of Twist Bioscience increased by 31% over the weekly session following the formalization of an AI drug discovery agreement with Eli Lilly. Under the structure, Twist supplies proprietary AbLab characterization workflows into Lilly TuneLab, generating direct data services revenue while enhancing synthetic biology integration in biopharma pipelines.
    Affected
    TWSTLLY
    Transmission
    Direct commercial partnership with a major pharmaceutical customer provides fee-based revenue and validates proprietary antibody discovery software models.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TWSTcommercial data services revenue and validation of antibody platformUp1-4wTwist surged over 31% after announcing partnership with Eli Lilly for Lilly TuneLab.
    LLYexpansion of AI-enabled preclinical pipeline discovery capacityUp1-3mEli Lilly integrates Twist Bioscience data services into TuneLab initiative.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month